InvestSMART

Acrux Limited (ASX:ACR)

ALERT: Price-sensitive ASX Announcement for ACR
Current share price for ACR : $0.011 -0.007 (-38.89%)+
Announcement
Release
31 Jul 2025 9:01AM
Price at Release
$0.018
Full Release
download
Summary
Acrux Limited has announced a licensing partnership in Saudi Arabia for the commercialization of its Dapsone 5% Gel. The agreement grants an exclusive license to a partner in Saudi Arabia for the registration, marketing, and distribution of the product, which is used for the treatment of acne vulgaris. Acrux will be responsible for the manufacturing and supply of the gel, while its partner will handle regulatory submissions and commercialization activities in the Saudi market. The partnership is in line with Acrux’s strategy to expand the international reach of its dermatology products and represents an important step in maximizing the value of its product portfolio through strategic collaborations in key global markets.
Key Points
  • Acrux Limited has entered a licensing partnership in Saudi Arabia for Dapsone 5% Gel.
  • The agreement provides exclusive rights to a Saudi partner for registration, marketing, and distribution.
  • Dapsone 5% Gel is indicated for the treatment of acne vulgaris.
  • Acrux will manufacture and supply the product.
  • The Saudi partner will handle regulatory submissions and commercialization.
  • The partnership supports Acrux's strategy to expand internationally.
  • This deal is expected to maximize the value of Acrux's product portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.